Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy.

Zheng P, Zhou C, Lu L, Liu B, Ding Y. · 2022

Read Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy. by Zheng P, Zhou C, Lu L, Liu B, Ding Y. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9465867.txt.

Description

Zheng and co-authors review elesclomol, a copper carrying drug that targets mitochondrial metabolism in cancer. The drug was first known as a source of oxidative stress. It is now linked to cuproptosis, a copper driven form of cell death. Its power depends on how much a cancer leans on mitochondrial energy.

Cancer stem cells lean hard on that energy supply. So do cells that resist platinum drugs or proteasome inhibitors. The review shows elesclomol hit all such cells hard. Its toxicity rides on moving copper ions into the cell. Past trials failed to show clear gains, yet safety was confirmed. The authors urge new trials in cancers with high mitochondrial metabolism. Pairing the drug with platinum or glycolysis blockers is a key plan.

Catalog record

CREATORZheng P, Zhou C, Lu L, Liu B, Ding Y.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE61 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9465867

Browse the full library · About the Tower of Babel